Skip to main content
SpringerLink
Log in

Maintenance pemetrexed too costly for NSCLC in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2010 values

Reference

  • Zeng X, et al. Cost-effectiveness of continuation maintenance pemetrexed after Cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the chinese health care system. Clinical Therapeutics 35: 54-65, No. 1, Jan 2013. Available from: URL: http://dx.doi.org/10.1016/j.clinthera.2012.12.013

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maintenance pemetrexed too costly for NSCLC in China. PharmacoEcon Outcomes News 671, 6 (2013). https://doi.org/10.1007/s40274-013-0131-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0131-1

Search

Navigation